Antithrombotic Treatments in Patients With SARS-CoV-2 Infection: From Current Evidence to Reasonable Recommendations - A Position Paper From the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology

被引：5
|
作者：
Patti, Giuseppe [1 ]
Lio, Veronica [1 ]
Cavallari, Ilaria [2 ]
Gragnano, Felice [3 ]
Riva, Letizia [4 ]
Calabro, Paolo [3 ]
Di Pasquale, Giuseppe [4 ]
Pengo, Vittorio [5 ,6 ]
Rubboli, Andrea [7 ]
机构：
[1] Univ Piemonte Orientale, Osped Maggiore Carita, Cattedra Cardiol, Novara, Italy
[2] Univ Campus Biomed, Rome, Italy
[3] Univ Campania Luigi Vanvitelli, Cattedra Cardiol, UOC Cardiol, AORN St Anna & San Sebastiano,UTIC, Caserta, Italy
[4] Osped Maggiore Bologna, UOC Cardiol, Bologna, Italy
[5] Univ Padua, Lab Ric Trombosi, Campus Biomed Pietro Abano, Padua, Italy
[6] Fdn Arianna Anticoagulaz, Bologna, Italy
[7] Osped S Maria Croci, UO Cardiol, AUSL Romagna, Dipartimento Cardiovasc, Ravenna, Italy
来源：
GIORNALE ITALIANO DI CARDIOLOGIA | 2020年 / 21卷 / 07期
关键词：
Coronavirus; Anticoagulant treatment; Antiplatelet therapy; Thrombosis; VENOUS THROMBOEMBOLISM PROPHYLAXIS; EAST RESPIRATORY SYNDROME; ORAL ANTICOAGULANTS; ATRIAL-FIBRILLATION; ESC GUIDELINES; MANAGEMENT; WARFARIN; MODEL; LOPINAVIR/RITONAVIR; COAGULOPATHY;
D O I：
10.1714/3386.33634
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Given the high prevalence of preexisting cardiovascular diseases and the increased incidence of adverse cardiovascular events in patients hospitalized for SARS-CoV-2 infection, the identification of optimal antithrombotic approaches in terms of risk/benefit ratio and outcome improvement appears crucial in this setting. In the present position paper we collected current evidence from the literature to provide practical recommendations on the management of antithrombotic therapies (antiplatelet and anticoagulant) in various clinical contexts prevalent during the SARS-CoV-2 outbreak: in-home management of oral anticoagulant therapy; interactions between drugs used in the SARS-CoV-2 infection and antithrombotic agents; in-hospital management of antithrombotic therapies; diagnosis, risk stratification and treatment of in-hospital thrombotic complications.
引用
收藏
页码：489 / 501
页数：13
相关论文
共 35 条
  • [31] Early 3-day course of remdesivir to prevent progression to severe Covid-19 in high-risk patients with hospital-acquired SARS-CoV-2 infection: preliminary results from two Italian outbreaks
    Meini, Simone
    Bracalente, Irene
    Bontempo, Giulia
    Longo, Benedetta
    De Martino, Maria
    Tascini, Carlo
    NEW MICROBIOLOGICA, 2022, 45 (04): : 304 - 307
  • [32] Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
    Pala, Laura
    Conforti, Fabio
    Saponara, Maristella
    De Pas, Tommaso
    Giugliano, Federica
    Sale, Emanuela Omodeo
    Jemos, Costantino
    Rubatto, Marco
    Agostini, Andrea
    Quaglino, Pietro
    Fava, Paolo
    Fierro, Maria Teresa
    Queirolo, Paola
    SEMINARS IN ONCOLOGY, 2020, 47 (05) : 302 - 304
  • [33] Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    Gorog, Diana A.
    Price, Susanna
    Sibbing, Dirk
    Baumbach, Andreas
    Capodanno, Davide
    Gigante, Bruna
    Halvorsen, Sigrun
    Huber, Kurt
    Lettino, Maddalena
    Leonardi, Sergio
    Morais, Joao
    Rubboli, Andrea
    Siller-Matula, Jolanta M.
    Storey, Robert F.
    Vranckx, Pascal
    Rocca, Bianca
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (02) : 125 - 140
  • [34] Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study
    Dina Averbuch
    Rafael de la Camara
    Gloria Tridello
    Nina Simone Knelange
    Tatiana A. Bykova
    Marianne Ifversen
    Veronika Dobsinska
    Mouhab Ayas
    Amir Ali Hamidieh
    Herbert Pichler
    Antonio Perez-Martinez
    Simone Cesaro
    Mikael Sundin
    Isabel Badell
    Peter Bader
    Jan-Erik Johansson
    Oana Mirci-Danicar
    Petr Sedlacek
    Catherine Paillard
    Brenda Gibson
    Sarah Lawson
    Nicolaus Kroeger
    Selim Corbacioglu
    Malgorzata Mikulska
    Jose Luis Piñana
    Jan Styczynski
    Per Ljungman
    Bone Marrow Transplantation, 2023, 58 : 558 - 566
  • [35] Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study
    Averbuch, Dina
    de la Camara, Rafael
    Tridello, Gloria
    Knelange, Nina Simone
    Bykova, Tatiana A.
    Ifversen, Marianne
    Dobsinska, Veronika
    Ayas, Mouhab
    Hamidieh, Amir Ali
    Pichler, Herbert
    Perez-Martinez, Antonio
    Cesaro, Simone
    Sundin, Mikael
    Badell, Isabel
    Bader, Peter
    Johansson, Jan-Erik
    Mirci-Danicar, Oana
    Sedlacek, Petr
    Paillard, Catherine
    Gibson, Brenda
    Lawson, Sarah
    Kroeger, Nicolaus
    Corbacioglu, Selim
    Mikulska, Malgorzata
    Pinana, Jose Luis
    Styczynski, Jan
    Ljungman, Per
    BONE MARROW TRANSPLANTATION, 2023, 58 (05) : 558 - 566
1234